Inclusion Criteria:

          1. Female patients ≥ 18 years of age

          2. Patients must have a confirmed diagnosis of high-grade serous epithelial ovarian
             cancer, primary peritoneal cancer, or fallopian tube cancer

          3. Patients must have platinum-resistant disease (defined as progression within 6 months
             from completion of a minimum of four cycles of platinum-containing therapy) Note: This
             should be calculated from the date of the last administered dose of platinum therapy
             to the date of the radiographic imaging showing progression. Patients who are
             platinum-refractory during front-line treatment are excluded

          4. Patients must have progressed on or after their most recent line of therapy Note:
             Progression must be determined radiographically and/or by CA-125 GCIG progression
             criteria

          5. Patients must be willing to provide an archival tumor tissue block or slides, or
             undergo procedure to obtain a new biopsy using a low risk, medically routine procedure
             for IHC confirmation of FRα positivity

          6. Patient's tumor must be positive for FRα expression as defined by the Ventana FOLR1
             (FOLR-2.1) CDx assay

          7. Patients must have at least one lesion that meets the definition of measurable disease
             by RECIST v1.1 (radiologically measured by the Investigator)

          8. Patients must have received at least 1 but no more than 3 prior systemic lines of
             anticancer therapy, and for whom single-agent therapy is appropriate as the next line
             of treatment:

               1. Adjuvant ± neoadjuvant considered one line of therapy

               2. Maintenance therapy (eg, bevacizumab, PARP inhibitors) will be considered as part
                  of the preceding line of therapy (ie, not counted independently)

               3. Therapy changed due to toxicity in the absence of progression will be considered
                  as part of the same line (ie, not counted independently)

               4. Hormonal therapy will be counted as a separate line of therapy unless it was
                  given as maintenance

          9. Patient must have an Eastern Cooperative Oncology Group Performance Status (ECOG PS)
             of 0 or 1

         10. Time from prior therapy:

               1. Systemic antineoplastic therapy (5 half-lives or 4 weeks, whichever is shorter)

               2. Focal radiation completed at least 2 weeks prior to first dose of study drug

         11. Patients must have stabilized or recovered (Grade 1 or baseline) from all prior
             therapy-related toxicities

         12. Major surgery must be completed at least 4 weeks prior to first dose and have
             recovered or stabilized from the side effects of prior surgery

         13. Patients must have adequate hematologic, liver and kidney functions defined as:

               1. Absolute neutrophil count (ANC) ≥ 1.5 x 109/L (1,500/μL)

               2. Platelet count ≥ 100 x 109/L (100,000/μL) without platelet transfusion in the
                  prior 10 days

               3. Hemoglobin ≥ 9.0 g/dL

               4. Serum creatinine ≤ 1.5 x upper limit of normal (ULN)

               5. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3.0 x ULN

               6. Serum bilirubin ≤ 1.5 x ULN (patients with documented diagnosis of Gilbert
                  syndrome are eligible if total bilirubin < 3.0 x ULN

               7. Serum albumin ≥ 2 g/dL

         14. Patients or their legally authorized representative must be willing and able to sign
             the informed consent form (ICF) and to adhere to the protocol requirements

         15. Women of childbearing potential (WCBP) must agree to use highly effective
             contraceptive method(s) (as defined in Section 5.9.6 in the protocol) while on study
             drug and for at least 3 months after the last dose of MIRV or at least 6 months after
             the last dose of paclitaxel, pegylated liposomal doxorubicin, or topotecan

         16. WCBP must have a negative pregnancy test within 4 days prior to the first dose of
             study drug

        Exclusion Criteria:

          1. Patients with endometrioid, clear cell, mucinous, or sarcomatous histology, mixed
             tumors containing any of the above histologies, or low-grade or borderline ovarian
             tumor

          2. Patients with primary platinum-refractory disease, defined as disease that did not
             respond to or has progressed within 3 months of the last dose of first line
             platinum-containing chemotherapy

          3. Patients with prior wide-field RT affecting at least 20% of the bone marrow

          4. Patients with > Grade 1 peripheral neuropathy per CTCAE v5.0

          5. Patients with active or chronic corneal disorders, history of corneal transplantation,
             or active ocular conditions requiring ongoing treatment/monitoring such as
             uncontrolled glaucoma, wet age-related macular degeneration requiring intravitreal
             injections, active diabetic retinopathy with macular edema, macular degeneration,
             presence of papilledema, and /or monocular vision

          6. Patients with serious concurrent illness or clinically relevant active infection,
             including, but not limited to the following:

               1. Active hepatitis B or C infection (whether or not on active antiviral therapy)

               2. HIV infection

               3. Cytomegalovirus infection

               4. Any other concurrent infectious disease requiring IV antibiotics within 2 weeks
                  before starting study drug

          7. Patients with history of multiple sclerosis or other demyelinating disease and/or
             Lambert-Eaton syndrome (paraneoplastic syndrome)

          8. Patients with clinically significant cardiac disease including, but not limited to,
             any one of the following:

               1. Myocardial infarction ≤ 6 months prior to first dose

               2. Unstable angina pectoris

               3. Uncontrolled congestive heart failure (New York Heart Association > class II)

               4. Uncontrolled ≥ Grade 3 hypertension (per CTCAE)

               5. Uncontrolled cardiac arrhythmias

          9. Patients assigned to PLD stratum only: Left ventricular ejection fraction (LVEF) below
             the institutional limit of normal as measured by echocardiography (ECHO) or multigated
             acquisition (MUGA) scan

         10. Patients with a history of hemorrhagic or ischemic stroke within six months prior to
             randomization

         11. Patients with a history of cirrhotic liver disease (Child-Pugh Class B or C)

         12. Patients with a previous clinical diagnosis of non-infectious interstitial lung
             disease (ILD), including noninfectious pneumonitis

         13. Patients with required use of folate-containing supplements (eg, folate deficiency)

         14. Patients with prior hypersensitivity to monoclonal antibodies

         15. Women who are pregnant or lactating

         16. Patients with prior treatment with MIRV or other FRα-targeting agents

         17. Patients with untreated or symptomatic central nervous system (CNS) metastases

         18. Patients with a history of other malignancy within 3 years prior to randomization.
             Note: does not include tumors with a negligible risk for metastasis or death (eg,
             adequately controlled basal-cell carcinoma or squamous-cell carcinoma of the skin, or
             carcinoma in situ of the cervix or breast